Overview

Safety Study of Roflumilast Cream 0.05% in Infants Aged 3 Months to Less Than 2 Years With Atopic Dermatitis

Status:
RECRUITING

Trial end date:
2026-06-01

Target enrollment:

Participant gender:

Summary

This study will assess the safety and tolerability of ARQ-151 cream 0.05% applied once a day for 4 weeks in infants with atopic dermatitis (eczema).

Phase:

PHASE2

Details

Lead Sponsor:

Arcutis Biotherapeutics, Inc.